Financial News · Live Terminal

Page 221 of 310

Research Alert: Biogen Q1 Earnings: Strong Beat Overshadowed By Lowered Full-year Eps Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Biogen delivered strong Q1 2026 results with non-GAAP EPS of $3.57 (+18% Y/Y) significantly exceeding the consensus of $2.95, while revenue of $2.478B (+2% Y/Y) beat expectations of $2.2B. Growth products sustained impressive momentum, generating $851M (+12% Y/Y), now representing one-third of total revenue, with LEQEMBI collaboration revenue up 80% Y/Y to $60M and the MS franchise showing better-than-expected resilience at $779M (-4% Y/Y). We view the continued acceleration of growth products as demonstrating successful portfolio diversification away from MS dependence. Management downgraded 2026 non-GAAP EPS guidance to $14.25-$15.25 from $15.25-$16.25, primarily reflecting acquired IPR&D charges. The proposed $5.6B Apellis acquisition, expected to close in Q2 2026, will add SYFOVRE and EMPAVELI to the growth portfolio and is anticipated to be accretive in 2027, in our view. We expect the combined revenue from these assets to grow in the mid-to-high teens for at least the next two years.

$BIIB

Research60d ago

Research Alert: Silgan Holdings Inc.: Strong Q1 Results Drive Fy 26 Eps Guidance Increase

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Silgan Holdings delivered solid Q1 2026 results that exceeded the high end of management's expected range, reporting net sales of $1.56B (+6% Y/Y, $51M above consensus) and adjusted EPS of $0.78 ($0.04 above consensus). The adjusted EPS declined from $0.82 in Q1 2025, reflecting higher tax rates and mixed volume dynamics across segments despite strong operational execution. The company demonstrated operational resilience amid challenging market conditions, with management's successful navigation of headwinds supporting the underlying strength of the business model. Management's confidence in raising full-year guidance underscores positive momentum despite near-term profitability pressures from tax and volume headwinds. We believe the solid performance above expectations and management's increased optimism reflect effective operational execution and the company's ability to deliver consistent results in a difficult operating environment.

$SLGN

Research60d ago

Research Alert: Ctsh Delivers Impressive Bookings Acceleration, With Strong Margin Performance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CTSH posted Q1 sales of $5.41B (+6% Y/Y), matching expectations, +4% ex-FX (matching Q4). Adjusted EPS of $1.40 beat the Street view ($1.33), with 10 bps of Y/Y operating margin expansion (to 15.6%) due to efficiency gains, including AI generating ~40% of company code (vs. ~30% prior estimates). FY 26 guidance was raised slightly with constant currency revenue growth of 4%-6.5% unchanged but operating margin improved to 16.0%-16.2% from a prior 15.9%-16.1% (EPS midpoint up $0.07 to $5.70). We see resilience given elevated macro uncertainty and AI competition fears, with medium-term support from continued strong bookings momentum, which grew 11% Y/Y to $29.6B on a TTM basis, accelerating from 5% growth in 2025. CTSH booked seven deals above $100M in Q1, with large deal contract value up 70% Y/Y. Employee metrics remain strong with voluntary attrition remaining steady at 12.3% and utilization improving to 85% (+200 bps Q/Q, flat Y/Y). CTSH is acquiring Astreya (AI-first managed services) for an undisclosed sum.

$CTSH

Research60d ago

Research Alert: Bg: Strong Q1 Earnings Beat And Guidance Raise; Earnings Trend To Improve

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BG delivered solid Q1 results with adjusted EPS of $1.83 (+1% Y/Y) beating the $0.87 consensus, while adjusted EBIT of $561M (+55% Y/Y) exceeded the $367M consensus. Strong performance across segments drove the beat, with Soy Processing & Refining adjusted EBIT up 56% to $377M and Softseed Processing surging 138% to $195M. The results demonstrate early benefits from the transformational Viterra acquisition, with integration proceeding ahead of expectations and synergies materializing across value chains. Management significantly raised full-year 2026 adjusted EPS guidance to $9.00-$9.50 (consensus is $8.41) from $7.50-$8.00, a substantial $1.25 midpoint increase reflecting strong execution and improving synergy visibility. We believe Viterra integration momentum should continue supporting earnings growth, while favorable EPA renewable volume obligations requiring over 60% higher biofuel production vs. 2025 levels should benefit crush margins and support the company's positive outlook and earnings trajectory.

$BG

Research60d ago

Research Alert: Avantor: Q1 Results Above Consensus Despite Challenging Operating Environment

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Shares of AVTR jumped in premarket trading as Q1 results topped estimates despite underlying weakness, with adjusted EPS of $0.17 beating consensus by $0.01 though down from $0.23 in the prior year. Net sales remained flat at $1,581.4M but organic revenue declined 4.1%, with both VWR Distribution & Services (-4.8%) and Bioscience & Medtech Products (-2.0%) experiencing organic declines. Management characterized VWR's performance as showing "stabilization" after prolonged weakness. The higher-margin Bioscience segment (23.8% adjusted operating margin vs VWR's 9.2%) demonstrated "improved execution" and represents a key focus for Revival transformation efforts, in our view. Profitability metrics showed significant compression, with adjusted EBITDA margin falling 310 basis points to 13.9%. Operating cash flow declined to $58.7M from $109.3M, indicating continued working capital pressures. AVTR reaffirmed full-year 2026 guidance, suggesting management confidence despite the challenging environment.

$AVTR

Research60d ago

Research Alert: Old Dominion Freight Beats Q1 Estimates; Improving Demand As Q1 Progressed

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Old Dominion reported Q1 2026 EPS of $1.14, down from $1.19 but beating consensus by $0.09, while revenue declined 2.9% to $1.33B, exceeding estimates by $21M. LTL tons per day fell 7.7%, but pricing discipline drove LTL revenue per hundredweight up 4.4% to $29.13, partially offsetting volume weakness. The company maintained industry-leading service standards with 99% on-time delivery and claims ratio below 0.1%, positioning ODFL for market share gains. Management expressed confidence in handling incremental volume as demand improves and emphasized winning share through superior service delivery. Operating ratio expanded 80 bps to 76.2% due to revenue deleveraging, though strong cash generation of $374M enabled $149M in shareholder returns. Full-year 2026 capex is expected at $265M for network expansion. Shares trade at 44x FY 26 consensus estimates vs. the five-year average of 30.8x, reflecting investor optimism over operational efficiency and pricing power.

$ODFL

Research60d ago

Research Alert: Teva Q1: Innovative Growth Drives Performance Amid Generics Headwinds

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Teva delivered solid Q1 2026 results with revenue of $3,982M (+2% Y/Y) and non-GAAP EPS of $0.53, beating consensus estimates of $0.46. The innovative portfolio drove growth with key brands generating $838M (+41% Y/Y), led by AUSTEDO at $578M (+41%), AJOVY at $196M (+35%), and UZEDY at $63M (+62%). This strong momentum in neuroscience products demonstrates the success of Teva's Pivot to Growth strategy, offsetting generics headwinds from lenalidomide competition. Management maintained 2026 revenue guidance of $16.4B-$16.8B but updated EPS expectations to $1.91-$2.11 due to the strategic $700M acquisition of Emalex Biosciences. The Emalex transaction adds ecopipam, a first-in-class treatment for pediatric Tourette syndrome with NDA submission expected in H2 2026. We believe this acquisition aligns with Teva's neuroscience focus and represents capital-efficient pipeline expansion; it will impact near-term margins with the expected IPR&D charge.

$TEVA

Research60d ago

Research Alert: Pag: Earnings Exceed Expectations Despite Challenging Backdrop

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Penske Automotive (PAG) posted Q1 adjusted EPS of $3.05 vs. $3.59 (-15%), ahead of the $2.88 consensus. The beat was driven by a stronger-than-expected top line, as revenue fell 1.1% to $7.86B ($150M ahead of consensus) and gross margin contracted 10 bps to 16.5% (10 bps short of consensus). Lower volumes drove the revenue decline, as vehicles sold fell 2.8% to 123,173 units. Notably, currency provided a meaningful revenue tailwind (~$228M), benefiting from PAG's international exposure, particularly in the U.K. (~30% of total revenue). PAG repurchased 170K shares for $26.4M in Q1 (~1.8% of total outstanding shares). Management also closed on the acquisition of dealerships expected to add $450M in annualized revenue in February. In our view, this was a solid release, as PAG's earnings exceeded expectations despite a difficult backdrop for auto dealerships. The stock traded 3% higher in pre-market trading. PAG's higher non-U.S. exposure relative to other major U.S.-based auto dealerships helped boost results.

$PAG

Research60d ago

Research Alert: Evr Delivers Record Q1, Showcasing Advisory Dominance And Operating Leverage

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:EVR delivered record Q1 2026 results with adjusted net revenues of $1.40B (+100% Y/Y), exceeding the $1.17B consensus, led by advisory fees of $1.24B (+123%). Adjusted EPS reached $7.53 versus $3.49 in the prior-year period ($2.10 ahead of consensus) demonstrating exceptional operating leverage. We view this as a win for EVR, as the firm effectively capitalized on improving M&A conditions and outperformed peers through its execution of transactions, including Warner Brothers Discovery's $110B sale and Devon Energy's $58B merger. The firm demonstrated operating efficiency, with adjusted operating margins expanding 870 bps to 25.3%. EVR continued talent expansion, ending with 182 investment banking SMDs versus 157 in the prior-year period, with three additional SMDs committed to joining later in 2026. The firm returned $673.3M to shareholders through dividends and share repurchases, while maintaining a balance sheet with $986M in cash, positioning it well for continued growth in the accelerating megadeal cycle.

$EVR

Research60d ago

Luca Mining Maintained at Buy at Stifel Canada After Campo Morado Drill Results; Price Target Kept at C$4.00

Stifel Canada on Wednesday maintained its buy rating on the shares of Luca Mining (LUCA.V) and its C$4.00 price target following drilling results from its Campo Morado mine in Mexico." Luca reported underground drill results from Campo Morado's Largo Norte zone with a weighted average grade of 2.05g/t Au, ~20% above Campo Morado's current M&I gold grade of 1.70g/t Au. Polymetallic intercepts adjacent to existing underground infrastructure support potential for lower capital intensity mineable tonnes with the drilling extending mineralization beyond the current resource boundary. We view the results as supportive of Campo Morado's upcoming 2H26 LoM plan update and expansion study, which outlines a potential path to double group production from ~55kozpa AuEq in 2026 to ~110kpa AuEq by 2029 via production growth and improved recoveries. At 0.23x LT P/NAV versus junior peers at 0.57x, or 5.4x 2026 P/CF versus junior peers at 7.8x, we continue to see multiple expansion potential as the Campo Morado Expansion project and the upcoming mine plan update improve visibility on Luca's growth profile," analyst Cole McGill wrote.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $1.33, Change: $-0.04, Percent Change: -2.92%

$LUCA.V

Research60d ago

Hemlo Mining Maintained at Buy at Stifel Canada Following Q1 Results; Price Target Kept at C$12.00

Stifel Canada on Wednesday maintained its buy rating on the shares of Hemlo Mining (HMMC.TO) and its C$12.00 price target following the company's first-quarter results."HMMC delivered a solid start to its first full quarter of ownership of the Hemlo Gold mine, including in-line total gold production (100% basis) of 34.8Koz (322Kt ore processed at 3.41g/t) and attributable gold production of 29.7Koz (+3.4% vs. our 28.7Koz). Mining successfully transitioned to owner-operator on March 16, 2026, two weeks ahead of schedule, with 97% contractor workforce uptake, and HMMC fully repaid its $100Mln Revolving Credit Facility (RCF) reducing net debt to $26.2Mln (from $93.0Mln at YE25). At Q1/26, HMMC held cash of $123.7Mln, higher vs. our $85.6Mln estimate - with full financial results scheduled for May 20, 2026. HMMC currently trades at 0.46x on P/NAV and 3.7/3.2x on FY27/28E EV/EBITDA vs. average mid-tier (0.1-0.5Moz) and intermediate (0.5-2.0Moz) gold producers under Stifel coverage at 0.67x and 4.5/3.8x, respectively. We continue to see Hemlo on a clear path to unlock value through underground reserve and resource growth and mine/mill optimization," analyst Ralph Profiti wrote.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$HMMC.TO

Research60d ago

Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.

$IONS

Research60d ago

Aecon Group Maintained at Buy at Stifel Canada Following Q1 Results; Price Target Kept at C$44.50

Stifel Canada on Wednesday reiterated its hold rating on the shares of Aecon Group (ARE.TO) and its C$44.50 price target following the engineering and construction company's first-quarter results."In 1Q26, Aecon delivered a 10.9% revenue beat and 19.7% EBITDA beat relative to consensus, but we are categorizing it as a neutral quarter. 1Q26 only accounts for ~9% of full year EBITDA (thus the absolute beat is only a modest positive) and the full year outlook remains unchanged. Additionally, the stock has increased 53.8% YTD (S&P/TSX: +5.9%) and the valuation is full at 25.2x 2027E P/E (10Y avg: 14.6x, N.A. peer group average: 22.5x). Valuation remains the basis for our HOLD rating and that view is unchanged, but we believe the company remains well positioned to benefit from Canadian government spending on nuclear, defense work and infrastructure," analyst Ian Gillies wrote.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ARE.TO

Research60d ago

Research Alert: Cni Q1: Eps Beats, Revenue Lags, Operational Gains Amid Headwinds

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CNI posted Q1 adjusted EPS of CAD1.80, topping our CAD1.73 estimate but missing the consensus CAD1.81 forecast. Revenue declined 1% to CAD4.38B, as 3% volume growth was offset by a 3% freight revenue per RTM decline from FX and carbon tax headwinds. The operating ratio deteriorated 80 bps to 64.2%, as cost inflation outpaced revenue growth despite operational improvements including record Q1 fuel efficiency and 8% employee productivity gains. Segment performance was mixed: grain/fertilizers surged 10% while metals/minerals fell 11%, though underlying momentum remained solid with 2% constant currency revenue growth. Management reiterated expectations for flattish RTM growth in FY 26, with EPS growth slightly exceeding volume growth and a continued CAD2.8B capex program. FCF surged 44% to CAD900M, supporting CAD869M in share repurchases. We view the strong operational metrics and cash generation positively, though margin pressure from inflationary costs and FX headwinds remains a near-term concern.

$CNI

Research60d ago

First Quantum Minerals Maintained at Buy at Stifel Canada Following Q1 Results; Price Target Kept at C$52.00

Stifel Canada on Wednesday maintained its buy rating on the shares of First Quantum Minerals (FM.TO) and its C$52.00 price target following the miner's first-quarter results."First Quantum reported Q1/26 adjusted EPS of ($0.18) vs. our $0.02 (consensus: $0.03) and EBITDA of $326Mln vs. our $316Mln. Q1/26 EPS was negatively impacted by higher interest ($0.06 impact) and income tax ($0.20 impact) while EBITDA includes hedge losses of $144Mln (EBITDA ex-hedge losses: $470Mln). Q1/26 copper production of 96.5Kt at C1 cash cost of $2.51/lb was stronger vs. our 84.2Kt at $2.69/lb. GOP Resolution No.27 (April 7, 2026) authorized removal, processing and export of Cobre Panama stockpiled ore with first copper expected in late Q2/26 and 30-40Kt of additional contained copper included in revised 2026 guidance to 405-475Kt (from 375-435Kt) as expected. The net impact incremental FY26 guidance reduces our implied EBITDA by $125Mln or -5%, including higher C1 cash costs to $2.15-2.40/lb (from $1.95-2.20/lb) due to supply chain and F/X risks, and lower gold production (-13% to 150-175Koz) reflecting timing of the gold transition at Guelb Moghrein," analyst Ralph Profiti wrote..(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$FM.TO

Research60d ago

Research Alert: Canadian National Railway Posts Mixed Q1 Results As Eps Beats, Revenue Lags

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Canadian National Railway (CNR) posted Q1 adjusted EPS of CAD1.80, topping our CAD1.73 estimate but missing consensus CAD1.81, while revenue declined 1% to CAD4.38B as 3% volume growth was offset by 3% freight revenue per RTM decline from FX and carbon tax elimination impacts. Operating ratio deteriorated 80 bps to 64.2% as cost inflation offset revenue pressure, with the company delivered record Q1 operational performance including fuel efficiency up 3%, car velocity up 6%, and employee productivity up 8%. Mixed commercial results saw grain/fertilizers grow 10% while metals/minerals declined 11%, with free cash flow up 44% to CAD900M supporting CAD869M in share repurchases. Management reiterated expectations for flattish RTM growth in 2026 with EPS growth slightly exceeding volume growth amid heightened demand risk from macroeconomic volatility and trade tensions. We view the strong operational metrics and cash generation positively, though revenue headwinds and margin pressure remain near-term concerns.

$CNR

Research60d ago

Research Alert: Gehc Q1 2026: Solid Revenue Growth Amid Margin Pressures And Revised Outlook

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GE HealthCare reported mixed Q1 2026 results with revenue of $5.1B, up 7.4% Y/Y (+2.9% organic), but adjusted EBIT margin contracted 150 bps to 13.5% due to operational challenges and inflationary pressures. Adjusted EPS of $0.99 declined modestly from $1.01 in the prior year, impacted by discrete PDx supplier issues, rising memory chip, oil, and freight costs, plus ongoing tariff impacts. Segment performance was mixed, in our view, with Pharmaceutical Diagnostics leading growth at +21.7% reported (+9.7% organic), while Patient Care Solutions declined -6.5% with EBIT margins contracting 500 bps to just 1.4%. Management reduced full-year adjusted EPS guidance to $4.80-$5.00 (from $4.95-$5.15) while maintaining organic revenue growth expectations of 3.0%-4.0%, which we view as achievable. The company expects to offset more than half of inflation impact through pricing and cost mitigation efforts, though margin pressures are expected to persist through 2026, given current challenging market conditions.

$GEHC

Research60d ago

Research Alert: Yum: Eps Beat On Taco Bell Strength And Kfc Expansion

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:YUM posted Q1 adjusted EPS of $1.50 (+15% Y/Y), beating the $1.39 consensus, while revenue reached $2.06B (+15% Y/Y), above the $2.04B consensus, on 3% global same-store sales and 4.6% net new store growth. Consolidated operating profit of $638M (+11%) beat the $622M consensus despite 110 bps margin contraction, as revenue growth offset cost pressures. We were impressed by strong same-store sales and unit growth pace; the highly franchised model (98% of stores) providing continued cost protection and capital efficiency. Management reiterated confidence in the long-term growth algorithm targeting 5% unit growth, 7% system sales growth ex-FX, and at least 8% core operating profit growth. Taco Bell delivered outstanding 8% same-store sales growth, outpacing broader QSR trends; KFC demonstrated strong global expansion with 7% unit growth and 70 bps margin expansion. Pizza Hut showed stabilization with flat same-store sales, but margins compressed 690 bps, reflecting ongoing category challenges.

$YUM

Research60d ago

Argus Downgrades Invesco to Hold From Buy

Invesco (IVZ) has an average rating of overweight and mean price target of $28.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$IVZ

Research60d ago

Research Alert: Lad: Q1 Earnings Well Ahead Of Expectations; Buybacks Impress

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Lithia Motors (LAD) posted Q1 adjusted EPS of $7.34 vs. $7.93 (-7%), well ahead of the $6.86 consensus. The beat was driven by stronger-than-expected revenue and margins, as net sales rose 1.0% to $9.27B ($50M ahead of consensus) and gross margin contracted 10 bps to 15.3% (10 bps ahead of consensus). LAD posted weaker gross margins across its New Vehicle (-50 bps) and Used Vehicle (-40 bps) segments, partially offset by stronger Aftersales results (+150 bps). LAD bought back 942K shares or 4.0% of its total outstanding shares for $259M in Q1 (an average price of $274.62/share). LAD said that stores acquired during Q1 are expected to generate $425M in annualized revenue. LAD shares are up in pre-market trading. We were particularly impressed by its buybacks. After disappointing earnings from other auto dealerships in recent days, LAD proved that its disciplined approach to acquisitions, cash returns to shareholders, and operational efficiency are paying off amid a difficult fundamental backdrop.

$LAD

Showing 4401-4420 of 6188